Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

Tanaka, Yoshiya; Kameda, Hideto; Saito, Kazuyoshi; Kaneko, Yuko; Tanaka, Eiichi; Yasuda, Shinsuke; Tamura, Naoto; Fujio, Keishi; Fujii, Takao; Kojima, Toshihisa; Anzai, Tatsuhiko; Hamada, Chikuma; Fujino, Yoshihisa; Matsuda, Shinya; Kohsaka, Hitoshi

doi:10.1186/s13075-018-1647-3

Table 2 Adjusted mean change in WPAI, Work Functioning Impairment Scale, DAS28-ESR, and QOL measures at week 52

From: Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

	PWs or HWs	TCZ-SC group	csDMARDs-alone group	Difference between TCZ-SC group − csDMARDs-alone group (95% confidence interval)	P value (TCZ-SC group vs csDMARDs-alone group)
WPAI
OWI (%)	PWs	−18.9	−19.0	0.1 (−6.3, 6.5)	0.978
Presenteeism (%)	PWs	−17.7	−17.2	−0.5 (−6.7, 5.6)	0.868
Absenteeism (%)	PWs	−7.1	−6.0	−1.1 (−4.8, 2.7)	0.580
Activity impairment (%)	Overall	−22.3	−15.8	−6.4 (−10.7, −2.2)	0.003
	PWs	−22.5	−19.4	−3.1 (−8.8, 2.7)	0.293
	HWs	−24.0	−14.5	−9.5 (−16.0, −2.9)	0.005
Work Functioning Impairment Scale
WFun	PWs	−3.2	−3.2	0.0 (−1.3, 1.3)	0.983
Disease activity
DAS28-ESR	Overall	−2.732	−1.388	−1.344 (−1.601, −1.087)	< 0.001
	PWs	−2.576	−1.577	−0.999 (−1.386, −0.612)	< 0.001
	HWs	−2.953	−1.279	−1.674 (−2.050, −1.298)	< 0.001
CDAI	Overall	−13.932	−10.340	−3.591 (−5.440, −1.742)	< 0.001
	PWs	−12.951	−11.679	−1.272 (−3.484, 0.939)	0.259
	HWs	−15.399	−9.427	−5.972 (−8.964, −2.980)	< 0.001
SDAI	Overall	−16.014	−11.521	−4.494 (−6.528, −2.459)	< 0.001
	PWs	−14.117	−12.338	−1.778 (−4.163, 0.607)	0.143
	HWs	−18.391	−11.388	−7.003 (−10.507, −3.499)	< 0.001
QOL
FAI	HWs	1.8	0.7	1.0 (0.0, 2.1)	0.054
EQ-5D	Overall	0.147	0.092	0.055 (0.023, 0.086)	< 0.001
	PWs	0.154	0.123	0.031 (−0.015, 0.077)	0.182
	HWs	0.162	0.075	0.087 (0.036, 0.137)	< 0.001
HAQ-DI	Overall	−0.355	−0.238	−0.117 (−0.207, −0.027)	0.011
	PWs	−0.349	−0.286	−0.063 (−0.176, 0.050)	0.274
	HWs	−0.381	−0.226	−0.155 (−0.305, −0.005)	0.042
K6	Overall	−2.2	−1.1	−1.2 (−1.8, −0.6)	< 0.001
	PWs	−1.9	−1.2	−0.6 (− 1.3, 0.0)	0.065
	HWs	−3.0	−1.1	−1.8 (−2.9, −0.8)	< 0.001

Adjusted-weight analysis by inverse probability treatment weighting method
Last observation carried forward method was applied for missing data due to patient discontinuation
CDAI clinical disease activity index, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, EQ-5D EuroQol 5 dimension, FAI Frenchay activities index, HAQ-DI health assessment questionnaire disability index, HW house worker, K6 6-item Kessler psychological distress scale, OWI overall work impairment, PW paid worker, QOL quality of life, SDAI simplified disease activity index, TCZ-SC tocilizumab by subcutaneous injection, WFun work functioning impairment scale, WPAI work productivity and activity impairment questionnaire

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us